Αποτελέσματα Αναζήτησης
9 Αυγ 2016 · Teva Pharmaceutical Industries has announced the launch of a generic version of imatinib mesylate, which is currently manufactured by Novartis and is sold under the brand name Gleevec.
Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. [2] Imatinib is a small molecule inhibitor targeting multiple tyrosine kinases such as CSF1R, ABL, c-KIT, FLT3, and PDGFR-β.
Imatinib inhibits BCR-ABL tyrosine kinase, the fusion protein created by the Philadelphia chromosome abnormality that characterizes chronic myeloid leukemia.
Φάρμακο. Ενεργά συστατικά. Ανατομική/θεραπευτική/χημική (ATC) ταξινόμηση. Τρόποι και περιορισμοί διάθεσης. Χαρακτηριστικά προϊοντος, οδηγίες χρήσης και λοιπή τεκμηρίωση. Φαρμακευτικά σκευάσματα. Δισκίο, επικαλυμμένο με υμένιο.
Five manufacturers of generic imatinib were used during this period: Accord, Sandoz, Teva, Dr. Reddy, Mylan; accord accounted for more than 50% of total usage. We analyzed the variation in quantitative PCR values, considering BCR/ABL cDNA copies/≥10,000 ABL copies corrected by the International Standard (IS).
Imatinib Mesylate. Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May 2001 and is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive ( ….
Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia (CML). It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as as well as fresh leukemic cells from ...
